ArticlePsychopharmacology2017
Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05803447 (Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Patients Suffering From Depression and Schizophrenia), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Patients Suffering From Depression and Schizophrenia
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.Molecular psychiatry · 2026Pooled it
- Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.Clinical drug investigation · 2025Pooled it
- Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.The international journal of neuropsychopharmacology · 2018Pooled it
- Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study.Schizophrenia bulletin · 2025Trial
- Memantine effects on auditory discrimination and training in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Memantine: updates from the past decade and implications for future novel therapeutic applications.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Article
- Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview.Indian journal of psychiatry · 2026Article
- Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer's or mixed dementia: a real-world analysis using the quality registry SveDem.Alzheimer's research & therapy · 2025Observational
- Pharmacological Treatments of Negative Symptoms in Schizophrenia-An Update.Journal of clinical medicine · 2024Review
- Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.Frontiers in psychiatry · 2024Review
- The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial.Iranian journal of psychiatry · 2023Article
- Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review.Journal of clinical medicine · 2023Review
- Management of cognitive and negative symptoms in schizophrenia.The mental health clinician · 2022Article
- European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Review
- Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.CNS drugs · 2022Review
- Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice.Psychopharmacology · 2022Article
- Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.Complex psychiatry · 2021Review
- EPA guidance on treatment of negative symptoms in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleWe examined whether memantine add-on to antipsychotic treatment is beneficial in schizophrenia treatment.
objectiveThis systematic review and meta-analysis aimed to achieve stronger evidence on the efficacy and safety of memantine add-on for treating schizophrenia.
methodsWe analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics. The primary outcomes were amelioration of negative symptoms and all-cause discontinuation. Dichotomous outcomes are presented as risk ratios (RRs), and continuous outcomes are presented as mean differences (MDs) or standardized mean differences (SMDs).
resultsEight studies (n = 448) were included. Although memantine add-on treatment was superior to placebo for ameliorating negative symptoms (SMD = -0.96, p = 0.006, I
conclusionsMemantine add-on treatment may be beneficial for treating psychopathological symptoms (especially negative symptoms) in schizophrenia patients. The negative-symptom effect size may be associated with younger adult schizophrenia patients.
Indexed as
Identifiers
28508107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.